The CHOP combination CT, administered every 21 days, is the standard for the treatment of advanced DLBCL for many years, with long-term disease-free survival in approximately 35% of patients. One of the newer developments is the addition of rituximab, a humanized anti-CD20 monoclonal antibody. The role of rituximab was first evaluated in elderly (>65 years) patients with DLBCL and the addition of rituximab to conventional CHOP (administered every 21 days, at standard doses) leads to a significant improvement in outcome. Eight cycles of rituximab-CHOP (R-CHOP) produced a complete response in 75% of patients versus 63% of CHOP alone (p = 0.005), with a significant 5-year survival benefit in terms of event-free (47 vs 29%), progression-free (54 vs 30%) and overall survival (58 vs 45%). The addition of rituximab did not substantially increase the toxicity of CHOP, even though a trend towards an increased risk of infections was observed after R-CHOP compared with CHOP. A cooperative American study in elderly patients comparing up-front CHOP with or without rituximab and with or without rituximab maintenance confirmed the GELA results, with a significant advantage for patients receiving rituximab, either as part of induction or maintenance therapy.
Rituxan® (rituximab) is FDA indicated for the treatment of patients with:
Milliman Care Guidelines® Ambulatory Care, 14th Edition, Rituximab
ACG: A-0448 (AC) says:
Rituximab is a recombinant monoclonal antibody that targets CD20, a protein expressed on the surface of B lymphocytes, causing cell death. For B-cell non-Hodgkin lymphomas, several literature and systematic reviews that included numerous randomized controlled trials found rituximab to be effective in improving progression-free and overall survival for several types of this disease in adults and children.